


--Ac-aa⁰-Cys¹-Gly²-aa³-aa⁴-aa⁵-aa⁶-aa⁷-Gly⁸-aa⁹-Cys¹⁰-NH₂ [2b, SEQ ID NO:2]--

A3



Please replace the paragraph at page 21, prenumbered lines 4-15, as follows:


--Subsequently, a three-dimensional structure of a complex compound of peptide [2a; SEQ ID NO:3] and a partial structure containing the DNA binding site of AP-1 were prepared by the use of SYBYL, and a molecular dynamics simulation was carried out according to the molecular dynamics calculation program AMBER (Oxford Molecular Co., GB) (Fundamentals of Protein Engineering Physics and Chemistry, published by Kyoritsu Shuppan, Page 192, 1991) by using the three-dimensional structure obtained above as an initial structure to obtain a plurality of three-dimensional structures of AP-1-cyclic peptide [2a; SEQ ID NO:3] complex in water.--

Please replace the paragraph at page 21, prenumbered lines 16-23, as follows:

--On the other hand, nuclear magnetic resonance (NMR) spectrum of peptide [2a; SEQ ID NO:3] was measured, and the result was treated according to a structural analysis software X-PLOR (MSI Co., USA) to obtain a plurality of three-dimensional structures of peptide [2a; SEQ ID NO:3] in water experimentally (Shinsei Kagaku Jikken Koza I, Proteins III, Pages 139-147, 1990, published by

Please replace the paragraph at page 21, prenumbered line 24, to page 22, prenumbered line 21, as follows:

--The experimentally obtained three-dimensional structures were compared with the three-dimensional structures of cyclic peptide [2a; SEQ ID NO:3] in the complex obtained from the molecular dynamics simulation. As a result, a high level of similarity was found out between eleven of the experimentally confirmed three-dimensional structures and fourteen of the three-dimensional structures obtained from molecular dynamics simulation in the partial three-dimensional structure of Gln-Leu-Asp-Leu-Ala [SEQ ID NO:4]. Based on this finding, it could be confirmed that the five atoms N_1 , N_2 , N_3 , N_4 and N_5 expressed by the following formula:



wherein N_1 represents an atom to which a donative hydrogen atom in a hydrogen-bond donating group is bonded or a hydrogen-bond accepting atom in a hydrogen-bond accepting group; N_3 represents a hydrogen-bond accepting atom in a hydrogen-bond accepting group; and N_2 , N_4 and N_5 independently represent an arbitrary carbon atom constituting a hydrophobic group, constitute a pharmacophore necessary for the binding to AP-1 and the expression of an antagonistic activity to AP-1 binding sequence (Souyaku Kagaku, Kagaku Dojin,

ALC
Pages 11-13, 1995).--

Please replace the list at page 52, prenumbered line 12, to page 53,
prenumbered line 28, as follows:

--As typical compounds of this invention, the following compounds can be referred to, for example, provided that Ac represents an acetyl group.

- A 7
- Ac-Cys-Gly-Gln-Leu-Asp-Leu-Ala-Leu-Gly-Cys-NH₂ [SEQ ID NO:5] (having a disulfide linkage between the first and tenth L-cysteine residues)
 - Ac-Cys-Gly-Gln-Leu-Ser-Leu-Ala-Leu-Gly-Cys-NH₂ [SEQ ID NO:6] (having a disulfide linkage between the first and tenth L-cysteine residues)
 - Ac-Cys-Gly-Gln-Leu-Asp-Leu-Ala-Gly-Gly-Cys-NH₂ [SEQ ID NO:7] (having a disulfide linkage between the first and tenth L-cysteine residues)
 - Ac-Cys-Gly-Gln-Leu-Asp-Leu-Ala-Asn-Gly-Cys-NH₂ [SEQ ID NO:8] (having a disulfide linkage between the first and tenth L-cysteine residues)
 - Ac-Cys-Gly-Gln-Leu-Ser-Leu-Ala-Asp-Gly-Cys-NH₂ [SEQ ID NO:9] (having a disulfide linkage between the first and tenth cysteine residues)
 - Ac-Cys-Gly-Asn-Leu-Asp-Leu-Ala-Asp-Gly-Cys-NH₂ [SEQ ID NO:3] (having a disulfide linkage between the first and tenth L-cysteine residues)
 - Ac-Asn-Cys-Gly-Asn-Leu-Leu-Ala-Leu-Gly-Ser-Cys-NH₂ [SEQ ID NO:10] (having a disulfide linkage between the second and eleventh L-cysteine residues)
 - Ac-Cys-Gly-Asn-Leu-Leu-Ala-Leu-Gly-Ser-Cys-NH₂ [SEQ ID NO:11] (having a disulfide linkage between the first and tenth L-cysteine residues)
 - Ac-Asn-Cys-Gly-Asn-Ala-Leu-Ala-Leu-Gly-Ser-Cys-NH₂ [SEQ ID NO:12] (having a disulfide linkage between the second and eleventh L-cysteine residues)
 - Ac-Cys-Gly-Asn-Leu-Leu-Ala-Leu-Gly-Asp-Cys-NH₂ [SEQ ID NO:13] (having

A7
Catal

a disulfide linkage between the first and tenth L-cysteine residues)

• Ac-Cys-Gly-Asn-Leu-Leu-Ser-Leu-Gly-Asp-Cys-NH₂ [SEQ ID NO:14] (having a disulfide linkage between the first and tenth L-cysteine residues)--

Please replace the paragraph at page 96, prenumbered lines 7-22, as follows:

A8
09830559-050701

--The peptide-bonded resin of general formula [7; SEQ ID NO:1] can be obtained by subjecting the resin of general formula [6] to a solid phase method. The construction of peptide chain by solid phase method is carried out by repeating a condensation of amino acid having an amino acid functional group protected with appropriate protecting group and de-protection of the protecting group of α -amino acid. Condensation of amino acid is carried out successively one by one from the terminal amino acid according to the order of amino acids in the sequence to be synthesized. The procedure of the solid phase method will be mentioned below. A series of reactions used therein are preferably carried out in an atmosphere of nitrogen. Any of the manual method and the method of using an automatic synthesizing apparatus may be adopted.--

Please replace the paragraph at page 99, prenumbered lines 20-25, as follows:

A9

--(4) The peptide of general formula (7; SEQ ID NO:1) can be obtained by acetylating a peptide-bonded resin having 10 residues. Concretely, it can be obtained by reacting a peptide-bonded resin of 10 residues with acetic anhydride in the presence or absence of an amine.--

Please replace the paragraph at page 100, prenumbered lines 16-19, as follows:

--The peptide of general formula [8; SEQ ID NO:1] can be obtained by removing the protecting group of amino side chain and the resin from the protected peptide resin of general formula [7; SEQ ID NO:1] in the presence of an acid.--

A10

Please replace the paragraph at page 101, prenumbered lines 21-26, as follows:

--The cyclic peptide of general formula [2; SEQ ID NO:1] can be obtained by forming a disulfide linkage between the cysteine side chains of the peptide of general formula [8; SEQ ID NO:1]. The formation of intramolecular disulfide linkage between two cysteine residues can be effected according to a known method.--

Please replace the paragraph at page 102, prenumbered lines 12-23, as follows:

--The cyclic peptides of general formula [2; SEQ ID NO:1] or salts thereof thus obtained can be isolated and purified according to conventional methods such as extraction, crystallization, gel filtration, liquid chromatography and/or column chromatography. For example, the isolation and purification can be effected by the gel filtration method using a gel filter such as Sephadex G-10, G-25 or the like, the column chromatography using a reverse phase type synthetic polymer resin or a chemically modified silica gel carrier and/or a high performance liquid chromatography, or the like.--

Please replace the paragraph at page 102, prenumbered lines 25-27, as follows:

--The cyclic peptide of general formula [2b; SEQ ID NO:2] can be obtained by the same method as Production Process 1.--

A11